Category:LapatinibLapatinibLapatinibLapatinibLapatinib%E3%83%A9%E3%83%91%E3%83%81%E3%83%8B%E3%83%96LapatinibLapatynibLapatinib%D0%9B%D0%B0%D0%BF%D0%B0%D1%82%D0%B8%D0%BD%D0%B8%D0%B1LapatinibLapatinib%D0%9B%D0%B0%D0%BF%D0%B0%D1%82%D0%B8%D0%BD%D1%96%D0%B1LapatinibQ420323%E6%8B%89%E5%B8%95%E6%9B%BF%E5%B0%BC
about
P2176
A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast CancerPhase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerCapecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast CancerValproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid TumorALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DLapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent ChemotherapyLapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric CancerA Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast CancerINST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer PatientsPhase I/II Study of Neoadjuvant Lapatinib in Breast CancerChemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric CancerNeoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast CancerStudy Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After SurgeryLapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast CancerLetrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast CancerRandomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy ExistsBrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreatic CancerLapatinib and Bevacizumab for Metastatic Breast CancerTykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast CancerA Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck CancerGW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast CancerCombination Of Lapatinib With Carboplatin, Paclitaxel and Trastuzumab In Metastatic Breast Cancer.Brain Metastasis in Breast Cancer PatientsEfficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast CancerA Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to TrastuzumabPhysician Liver Function Test (LFT) Monitoring for Tykerb PtsPazopanib, Lapatinib or Trastuzumab in Subjects With Solid TumorsA Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or CarcinosarcomaPAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast CancerA Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of LapatinibLapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast CancerLapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From ChinaConcentration and Activity of Lapatinib in Vestibular SchwannomasLapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck CancerLapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal CancerStudy Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast CancerLapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract CancerGW572016 to Treat Recurrent Malignant Brain TumorsStudy Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast CancerS0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer
P4844
Survivin in Insulin-Like Growth Factor-Induced Resistance to Lapatinib in Head and Neck Squamous Carcinoma CellsTherapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer RegistryLapatinib-Loaded Nanocapsules Enhances Antitumoral Effect in Human Bladder Cancer CellGlucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast cancer cells through autophagy perturbationLncRNAs GIHCG and SPINT1-AS1 Are Crucial Factors for Pan-Cancer Cells Sensitivity to LapatinibOncofertility counselling in premenopausal women with HER2-positive breast cancerHER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells(-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo
P921
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Lapatinib
@de
Lapatinib
@es
Lapatinib
@it
Lapatinib
@nl
Lapatinib
@sh
Lapatinib
@sr
Lapatinib
@vi
lapatinib
@en
lapatinib
@fr
lapatinib
@pt
type
label
Lapatinib
@de
Lapatinib
@es
Lapatinib
@it
Lapatinib
@nl
Lapatinib
@sh
Lapatinib
@sr
Lapatinib
@vi
lapatinib
@en
lapatinib
@fr
lapatinib
@pt
altLabel
FMM
@en
GW 572016
@en
GW572016
@en
LAP016
@en
Lapatinib
@ru
Lapatinib
@zh
N-{3-chloro-4-[(3-fluorobenzyl ...... yl)-2-furyl]-4-quinazolinamine
@en
N-{3-chloro-4-[(3-fluorophenyl ...... )-2-furanyl]-4-quinazolinamine
@en
Tykerb
@de
Tykerb
@es
prefLabel
Lapatinib
@de
Lapatinib
@es
Lapatinib
@it
Lapatinib
@nl
Lapatinib
@sh
Lapatinib
@sr
Lapatinib
@vi
lapatinib
@en
lapatinib
@fr
lapatinib
@pt